Ignite Creation Date:
2025-12-24 @ 2:44 PM
Ignite Modification Date:
2026-01-29 @ 12:57 PM
Study NCT ID:
NCT01503359
Status:
COMPLETED
Last Update Posted:
2016-09-16
First Post:
2011-12-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D012559', 'term': 'Schizophrenia'}], 'ancestors': [{'id': 'D019967', 'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D012521', 'term': 'Sarcosine'}], 'ancestors': [{'id': 'D034442', 'term': 'N-substituted Glycines'}, {'id': 'D005998', 'term': 'Glycine'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 70}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-09', 'completionDateStruct': {'date': '2016-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-09-15', 'studyFirstSubmitDate': '2011-12-30', 'studyFirstSubmitQcDate': '2012-01-03', 'lastUpdatePostDateStruct': {'date': '2016-09-16', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-01-04', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Assessment of sarcosine vs. placebo impact on schizophrenia symptoms using Positive and Negative Syndrome Scale (PANSS).', 'timeFrame': '6 months', 'description': 'Both arms, every visit'}], 'secondaryOutcomes': [{'measure': 'Impact assessment of sarcosine versus placebo on the parameters of quality of life (QoL) and sexual functioning.', 'timeFrame': '6 months', 'description': 'Both arms, every visit'}, {'measure': 'Impact assessment of sarcosine versus placebo on depressive symptoms using Calgary Depression Scale for Schizophrenia.', 'timeFrame': '6 months', 'description': 'Both arms, every visit'}, {'measure': 'Impact assessment of sarcosine versus placebo on cognitive functions using Wisconsin Card Sort Test, Trail Making Test and Stroop Test.', 'timeFrame': '6 months', 'description': 'Both arms, before and after taking sarcosine or placebo'}, {'measure': 'Impact assessment of sarcosine versus placebo on oxidative stress parameters (T-BARS).', 'timeFrame': '6 months', 'description': 'Both arms, before and after taking sarcosine or placebo'}, {'measure': 'Impact assessment of sarcosine versus placebo on brain metabolism parameters (magnetic resonance spectroscopy).', 'timeFrame': '6 months', 'description': 'Both arms, before and after taking sarcosine or placebo'}, {'measure': 'Impact assessment of sarcosine versus placebo on oculomotoric parameters (saccadic and antisaccadic task in electrooculography).', 'timeFrame': '6 months', 'description': 'Both arms, before and after taking sarcosine or placebo'}, {'measure': 'Impact assessment of sarcosine versus placebo on blood levels of glycine, sarcosine, BDNF and MMP-9.', 'timeFrame': '6 months', 'description': 'Both arms, before and after taking sarcosine or placebo'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['glutamic acid', 'sarcosine', 'NMDA', 'schizophrenia'], 'conditions': ['Schizophrenia']}, 'referencesModule': {'references': [{'pmid': '10719161', 'type': 'BACKGROUND', 'citation': 'Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev. 2000 Mar;31(2-3):342-9. doi: 10.1016/s0165-0173(99)00050-8.'}, {'pmid': '1695402', 'type': 'BACKGROUND', 'citation': "Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990 Jul;13(7):272-6. doi: 10.1016/0166-2236(90)90108-m."}, {'pmid': '9384954', 'type': 'BACKGROUND', 'citation': 'Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996 Jan-Feb;3(5):241-53. doi: 10.3109/10673229609017192.'}, {'pmid': '10873924', 'type': 'BACKGROUND', 'citation': 'Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry. 2000 Jul;157(7):1141-9. doi: 10.1176/appi.ajp.157.7.1141.'}, {'pmid': '15502972', 'type': 'BACKGROUND', 'citation': 'Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005 Apr;179(1):144-50. doi: 10.1007/s00213-004-2032-2. Epub 2004 Oct 21.'}, {'pmid': '11532718', 'type': 'BACKGROUND', 'citation': 'Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001 Sep;158(9):1367-77. doi: 10.1176/appi.ajp.158.9.1367.'}, {'pmid': '11806864', 'type': 'BACKGROUND', 'citation': 'Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2001 Dec;4(4):385-91. doi: 10.1017/S1461145701002590.'}, {'pmid': '1654746', 'type': 'BACKGROUND', 'citation': 'Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991 Oct;148(10):1301-8. doi: 10.1176/ajp.148.10.1301.'}, {'pmid': '17659263', 'type': 'BACKGROUND', 'citation': 'Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008 Jan 1;63(1):9-12. doi: 10.1016/j.biopsych.2007.04.038. Epub 2007 Jul 20.'}, {'pmid': '16780811', 'type': 'BACKGROUND', 'citation': 'Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006 Sep 15;60(6):645-9. doi: 10.1016/j.biopsych.2006.04.005. Epub 2006 Jun 14.'}, {'pmid': '11588613', 'type': 'BACKGROUND', 'citation': 'Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport. 2001 Sep 17;12(13):2971-4. doi: 10.1097/00001756-200109170-00043.'}, {'pmid': '8036251', 'type': 'BACKGROUND', 'citation': 'McBain CJ, Mayer ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev. 1994 Jul;74(3):723-60. doi: 10.1152/physrev.1994.74.3.723. No abstract available.'}, {'pmid': '10628529', 'type': 'BACKGROUND', 'citation': 'Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999 Nov-Dec;33(6):523-33. doi: 10.1016/s0022-3956(99)00029-1.'}, {'pmid': '15023571', 'type': 'BACKGROUND', 'citation': 'Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004 Mar 1;55(5):452-6. doi: 10.1016/j.biopsych.2003.09.012.'}, {'pmid': '9798069', 'type': 'BACKGROUND', 'citation': 'Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry. 1998 Oct 15;44(8):667-74. doi: 10.1016/s0006-3223(98)00151-6.'}, {'pmid': '16625590', 'type': 'BACKGROUND', 'citation': 'Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev. 2006 Apr 19;2006(2):CD003730. doi: 10.1002/14651858.CD003730.pub2.'}, {'pmid': '14684435', 'type': 'BACKGROUND', 'citation': 'West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci. 2003 Nov;1003:53-74. doi: 10.1196/annals.1300.004.'}, {'pmid': '15708298', 'type': 'BACKGROUND', 'citation': 'Yurgelun-Todd DA, Coyle JT, Gruber SA, Renshaw PF, Silveri MM, Amico E, Cohen B, Goff DC. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005 Jan 30;138(1):23-31. doi: 10.1016/j.pscychresns.2004.11.006.'}, {'pmid': '7751957', 'type': 'BACKGROUND', 'citation': 'Zafra F, Aragon C, Olivares L, Danbolt NC, Gimenez C, Storm-Mathisen J. Glycine transporters are differentially expressed among CNS cells. J Neurosci. 1995 May;15(5 Pt 2):3952-69. doi: 10.1523/JNEUROSCI.15-05-03952.1995.'}, {'pmid': '26501260', 'type': 'DERIVED', 'citation': 'Strzelecki D, Podgorski M, Kaluzynska O, Stefanczyk L, Kotlicka-Antczak M, Gmitrowicz A, Grzelak P. Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. Int J Mol Sci. 2015 Oct 15;16(10):24475-89. doi: 10.3390/ijms161024475.'}, {'pmid': '26306650', 'type': 'DERIVED', 'citation': 'Strzelecki D, Podgorski M, Kaluzynska O, Gawlik-Kotelnicka O, Stefanczyk L, Kotlicka-Antczak M, Gmitrowicz A, Grzelak P. Supplementation of antipsychotic treatment with sarcosine - GlyT1 inhibitor - causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. Neurosci Lett. 2015 Oct 8;606:7-12. doi: 10.1016/j.neulet.2015.08.039. Epub 2015 Aug 22.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of study is to determine whether dietary supplement sarcosine is effective in treatment of schizophrenia. The investigators will assess impact of sarcosine on quality of life and sexual functioning. In this project the investigators will also measure glycine, sarcosine, BDNF, MMP-9 levels and oxydative stress parameters in blood, brain glutamatergic metabolism parameters in magnetic resonance spectroscopy and oculomotoric changes in electrooculography.', 'detailedDescription': 'Glutamic acid is the largest excitatory neurotransmitter in the central nervous system, the population of glutamatergic neurones represents approximately 50% of all neurones in the brain. Being closely dependent on the inhibitory GABA system, the glutamate system is responsible for the transmission and modulation of the majority of brain signals and connected with dopaminergic and serotonergic systems. The glutamate system plays an important role in the pathogenesis of schizophrenia. NMDA receptor antagonists, including phencyclidine, ketamine and MK-801, cause symptoms similar to those found in schizophrenia, as well as deterioration of mental state in patients with schizophrenia. What is important from a theoretical point of view NMDA agonists also cause negative symptoms which are not observed after amphetamine or other drugs intoxications. Based on these observations, it was assumed that normalization of glutamatergic transmission may result in an improvement in schizophrenia symptomatology.\n\nAccording to the assumptions of this hypothesis, attempts were made to stimulate transmission within this system. Due to the high risk of excitotoxic effects induction therapy with glutamic acid is not administered (hyperactivity of glutamatergic system, leading to nerve cell damage was observed in neurodegenerative diseases). Along with glutamic acid and voltage changes dependent on another glutamatergic receptor - AMPA, presence of glycine is necessary to stimulate the NMDA receptor. This widely distributed amino acid, an important element of protein chains, is present in a daily diet (average consumption amounts to 2g/day). In addition to building properties, it is of paramount importance in the central nervous system. As a primary transmitter in glycinergic neurones it belongs to the class I of neurotransmitters. Moreover, it also plays a role as a co-agonist and a modulator, for example in the glutamatergic system. Glutamic acid is released from nerve endings into the synaptic cleft, where it is re-uptaken and dispersed, which, in consequence, results in a rapid decline in its concentration in the vicinity of NMDA receptors. As a result, the time of receptor binding is short. Intrasynaptic glycine turnover is different - it resides inside the synapses permanently, depending on the concentration and, to a greater or lesser extent, binds to a modulatory site. Glial cells, with identified glycine transport system (GlyT-1) are responsible for maintaining a stable level of glycine in neuronal junctions. New research on inhibitors of this transport system (GTI) eg. sarcosine, which may have similar or better effects to glycine administration, have begun. Glycine does not bind to all the modulatory sites on NMDA receptor in vivo, and augmentation of this saturation intensifies glutamatergic transmission. This phenomenon is particularly observed in individuals with relatively low (not sufficient for maximum saturation of the receptor site) levels of synaptic glycine.\n\nWe hypothesize that supplementation of sarcosine helps achieve betterment in symptomatology, general quality of life and also cognitive functioning and other prefrontal derivatives, eg. oculomotor functions.\n\nTo extend research we planned assessing blood levels of glycine, sarcosine but also other parameters involved in glutamatergic transmission such as BDNF and metalproteinase MMP-9. Knowing excitotoxic properties of glutamate TBARS (thiobarbituric acid reactive substances) - oxidative stress related will be assessed.\n\nMethodology of the study. We plan to enroll 60-70 patients in stable mental state meeting criteria for schizophrenia according to ICD-10 with predominant negative symptoms (minimum of 21 points and severity of each negative symptom at least 3 points in PANSS-Negative subscale).\n\nMain study part will be continued for 26 weeks (T0-T26) and 10 visits (W1-W10). The preceding 12-week period (W0-W1) will be used for evaluation of stability of mental state and pharmacotherapy.\n\nPatients on visit T0 will be randomized to two comparable groups of 30 patients (sarcosine and control group). Researchers and patients will not have information on the administered treatment.\n\nDuring the study patients will receive previous antipsychotic treatment (at least 3-month without dosage change). Mental stability will be assessed during the preceding period (W1 and W0 visit - 12 weeks before W1). Sarcosine (or placebo) will be augmented between visits W1 and W9, the subsequent period (between W9 and W10), will be used to evaluate the consequences of withdrawal sarcosine (and placebo).\n\nInformation on the history of the disease, and current mental status will be obtained during the psychiatric examination, in part, standardized by the use of commonly accepted psychiatric scales (PANSS, Calgary Depression Scale, CGI, SAS and quality of life and sexual activity scales). Assessment of the use of psychiatric scales will be used on each of the visits.\n\nAs the basic tools used to study cognitive functioning test Wisconsin Card Sorting (WCST), Trail Making Test (TMT) and Stroop Test will be used. Psychological testing will be performed by a psychologist on visits W1, W6 and W9.\n\nAssessment of metabolism of glycine and glutamic acid in brain tissue in the frontal cortex and hippocampus using magnetic resonance spectroscopy, electrooculography, parameter of oxidative stress - T-BARS and blood assessments (glycine, sarcosine, BDNF and MMP-9) will be performed on visits W1 and W9.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n\\- Diagnosis of schizophrenia (ICD-10)\n\nOther criteria related to the diagnosis verified during the selection visit:\n\n* The score for the PANSS negative symptoms subscale ≥ 21,\n* Severity of individual symptoms in the PANSS positive symptoms subscale may not exceed 3 points.\n\nExclusion Criteria:\n\nGeneral\n\n* lack of written informed consent,\n* risk of noncompliance during the study period,\n* patients who can not be assessed throughout the study period (eg. due to travel or vacations),\n* pregnancy or breastfeeding,\n* women of childbearing potential not using effective contraception (ie. birth control pill, surgical sterilization, hormonal contraceptive injection, IUD, contraceptive implant, patch, or condoms),\n* participation in another clinical study, currently or within 3 months before the visit of a selection panel\n* patients previously subjected to selection for this study.\n\nMedical and Therapeutic Criteria Associated with schizophrenia\n\n* patients in acute psychosis, severe symptoms of productive,\n* patients taking clozapine,\n* declaring suicidal tendencies, history of committing suicide in the past year.\n\nAssociated with other psychiatric disorders\n\n* patients currently meeting criteria for ICD-10 diagnosis of mental disorder other than schizophrenia (in the last 6 months before the visit of a selection), confirmed by the MINI questionnaire\n* patients showing a prevalent and / or severe symptoms of depression (even without meeting criteria for major depressive episode according to ICD-10 criteria),\n* patients ever diagnosed with lifetime bipolar disorder,\n* patients with severe personality disorders, particularly type of antisocial, borderline, or histrionicznego that could affect the assessment of test results.\n\nOther\n\n* abuse or addiction to alcohol or psychoactive substances (excluding nicotine) within the last 6 months, according to the criteria of ICD-10, confirmed by the MINI questionnaire,\n* disturbances occurring in the form of somatic according to ICD-10 criteria,\n* Delirium or dementia according to ICD-10 criteria,\n* current diagnosis of neurological diseases (eg, stroke, seizures, migraine, multiple sclerosis),\n* liver failure (ie, cirrhosis or active liver disease), diagnosed acute or chronic hepatitis,\n* severe or uncontrolled somatic disease that could affect the course of the study (eg cancer, cardiovascular, respiratory, metabolic or oral, severe renal failure, unstable diabetes type I or II, morbid obesity, untreated or uncontrolled hypertension, clinically significant blood),\n* thyroid dysfunction (especially hypothyroidism) untreated or uncontrolled, T - thyroid hormones treatment started, terminated or modified in the 3 months before the selection visit,\n* hormone replacement therapy started, terminated or modified in the 3 months before the selection visit.\n* recognized disorders of hemostasis,\n\nAssociated with a prior or concomitant treatment Particular caution should be maintained when using drugs likely to affect the central nervous system - their mechanism of action could affect the course of the study. Use of these substances after the selection visit is not allowed.'}, 'identificationModule': {'nctId': 'NCT01503359', 'acronym': 'PULSAR', 'briefTitle': 'Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia', 'organization': {'class': 'OTHER', 'fullName': 'Medical University of Lodz'}, 'officialTitle': 'Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.', 'orgStudyIdInfo': {'id': 'PULSAR'}, 'secondaryIdInfos': [{'id': 'N N402 268836', 'type': 'OTHER_GRANT', 'domain': 'Ministry of Science and Higher Education, Poland'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Dietary Supplement: Sarcosine', 'description': 'Sarcosine Group', 'interventionNames': ['Dietary Supplement: Sarcosine']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Control Group', 'interventionNames': ['Dietary Supplement: Sarcosine']}], 'interventions': [{'name': 'Sarcosine', 'type': 'DIETARY_SUPPLEMENT', 'otherNames': ['glycine transporter inhibitor', 'GlyT1 inhibitor'], 'description': 'Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.\n\nPlacebo group patients will receive 2 grams of placebo once a day in the morning for 6 months.', 'armGroupLabels': ['Dietary Supplement: Sarcosine', 'Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92-216', 'city': 'Lodz', 'state': 'Czechosłowacka 8/10', 'country': 'Poland', 'facility': 'Central Clinical Hospital', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}], 'overallOfficials': [{'name': 'Dominik Strzelecki, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Department of Affective and Psychotic Disorders, Medical University of Lodz'}, {'name': 'Jolanta Rabe-Jabłońska, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Department of Affective and Psychotic Disorders, Medical University of Lodz'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Medical University of Lodz', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Dominik Strzelecki MD PhD', 'investigatorAffiliation': 'Medical University of Lodz'}}}}